ALSAF.PA +13.57% to €0.92 on EURONEXT after hours 17 Mar 2026: €1.30 target

ALSAF.PA stock jumped 13.57% to €0.92 in EURONEXT after hours trading on 17 Mar 2026, making it one of the session’s top gainers. The move followed light volume, with 6,161.00 shares traded, and pushed the price above the session low of €0.81.

Safe Orthopaedics SA (ALSAF.PA) remains a micro-cap healthcare name with a market cap of €8,140.00. This note combines price action, ratios, and Meyka AI model output to frame short-term upside and the material risks for traders and investors on EURONEXT, using Meyka AI as an AI-powered market analysis platform.

ALSAF.PA stock price action and after-hours context

ALSAF.PA stock rose 13.57% in after-hours trade to €0.92, up €0.11 from the prior close of €0.81. Volume remains low at 6,161.00 versus an average of 10,329.00, so price moves can reflect thin-market flows.

The stock traded between €0.81 and €0.92 intraday and sits below the 50-day average of €1.00 and the 200-day average of €1.77, highlighting a technical gap between recent momentum and longer-term trend.

Drivers behind the rally and immediate news flow

There is no new public earnings release for Safe Orthopaedics; the next earnings date is listed as 01 Dec 2025. The after-hours gain appears driven by a short-term technical rebound and sector rotation into small healthcare names.

Traders cited in-market technicals such as an oversold oscillator and a bounce off recent support, rather than company-specific filings, as the primary catalyst for today’s top-gainer status on EURONEXT.

Financials and valuation: stark ratios for ALSAF.PA stock

Safe Orthopaedics reports EPS -9,792.48, a deeply negative bottom line that removes a simple PE comparison. Enterprise Value to Sales stands at 46.55, signaling a valuation mismatch versus peers.

Liquidity and balance-sheet metrics show strain: current ratio 0.03 and interest coverage -36.60, which point to near-term funding and operational risks for the company.

Technical indicators and short-term outlook for ALSAF.PA stock

Momentum indicators are mixed: RSI 43.37 and MACD histogram near 0.00 indicate neutral-to-weak momentum. Bollinger Bands show a middle band at €0.91, suggesting current price is close to a short-term mean.

Given thin volume and an ATR of €0.10, traders should expect volatility. A break above €1.00 (50-day average) would invite more buyers; failure to hold €0.81 raises downside risk to the recent low.

Meyka AI grade, forecast and price targets

Meyka AI rates ALSAF.PA with a score out of 100: Score 67.59 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a quarterly price of €1.30, a monthly level of €0.97, versus the current price €0.9199. The quarterly projection implies an upside of 41.33% from today’s price. Forecasts are model-based projections and not guarantees.

Trading considerations, sector comparison and risk factors

ALSAF.PA operates in the Healthcare Medical Instruments sector where average PE sits near 29.36; ALSAF.PA lacks comparability due to negative earnings and extreme balance-sheet metrics. Investors should weigh the sector’s defensive profile against company-specific execution risk.

Key risks include low liquidity, substantial negative cash flow per share, and high enterprise value versus sales. Position sizes should be small and stop levels strict for traders engaging this top gainer on EURONEXT.

Final Thoughts

ALSAF.PA stock led after-hours gainers on 17 Mar 2026, rising 13.57% to €0.92 on EURONEXT on relatively light volume. The move reflects a short-term technical rebound rather than new company disclosures. Financially, Safe Orthopaedics shows severe operational stress: EPS -9,792.48, current ratio 0.03, and EV/Sales 46.55. Meyka AI’s forecast model projects a quarterly target of €1.30, implying an upside of 41.33% from €0.9199. That projection provides a clear upside scenario, but it must be balanced with high liquidity risk and weak cash metrics. Traders who prefer event-driven or momentum setups may find short-term opportunity, while longer-term investors should wait for improved fundamentals or clearer funding progress. For further company detail consult Safe Orthopaedics’ site and our Meyka page for live updates and charts.

Sources: Safe Orthopaedics website and company profile data FinancialModelingPrep image/profile — forecasts are model outputs and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.